Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bella Ungar

Showing results (31-40 of 87) with videos related to

Pageof 9
Sort By:
United European Gastroenterology Journal|September 7, 2025
Vedolizumab Achieves Pan-Enteric Mucosal Healing in Crohn's Disease: A Prospective Observational StudyOffir Ukashi, Adi Lahat, Bella Ungar, et al.
United European Gastroenterology Journal|March 28, 2020
Lower adalimumab trough levels are associated with higher bowel wall thickness in Crohn's diseaseBella Ungar, Zohar Ben-Shatach, Limor Selinger, et al.
Gut|September 18, 2013
The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximabBella Ungar, Yehuda Chowers, Miri Yavzori, et al.
Biomedicines|June 28, 2023
Do Vedolizumab trough Levels Predict the Outcome of Subsequent Therapy in Inflammatory Bowel Disease?Asaf Levartovsky, Ido Cohen, Chaya Mushka Abitbol, et al.
Clinics and Research in Hepatology and Gastroenterology|March 12, 2014
Expression of IL-2, IL-17 and TNF-alpha in patients with Crohn's disease treated with anti-TNF antibodiesLior H Katz, Uri Kopylov, Ella Fudim, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 9, 2025
Performance of gastroenterologists and multimodal LLMs in endoscopic EREFS scoring of Eosinophilic EsophagitisAsaf Levartovsky, Lior Dar, Shmuel Fay, et al.
International Journal of Colorectal Disease|April 17, 2020
Infliximab levels and antibodies in IBD-related peripheral arthralgiaAsaf Levartovsky, Bella Ungar, Miri Yavzori, et al.
Gut|April 22, 2015
Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar RemsimaShomron Ben-Horin, Miri Yavzori, Itai Benhar, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 14, 2022
Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease - a retrospective studyMoran Livne-Margolin, Daniel Ling, Shani Attia-Konyo, et al.
United European Gastroenterology Journal|March 28, 2020
A novel PillCam Crohn's capsule score (Eliakim score) for quantification of mucosal inflammation in Crohn's diseaseRami Eliakim, Doron Yablecovitch, Adi Lahat, et al.
Pageof 9

Showing results (31-40 of 87) with videos related to

Sort By:
Pageof 9
United European Gastroenterology Journal|September 7, 2025
Vedolizumab Achieves Pan-Enteric Mucosal Healing in Crohn's Disease: A Prospective Observational StudyOffir Ukashi, Adi Lahat, Bella Ungar, et al.
United European Gastroenterology Journal|March 28, 2020
Lower adalimumab trough levels are associated with higher bowel wall thickness in Crohn's diseaseBella Ungar, Zohar Ben-Shatach, Limor Selinger, et al.
Gut|September 18, 2013
The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximabBella Ungar, Yehuda Chowers, Miri Yavzori, et al.
Biomedicines|June 28, 2023
Do Vedolizumab trough Levels Predict the Outcome of Subsequent Therapy in Inflammatory Bowel Disease?Asaf Levartovsky, Ido Cohen, Chaya Mushka Abitbol, et al.
Clinics and Research in Hepatology and Gastroenterology|March 12, 2014
Expression of IL-2, IL-17 and TNF-alpha in patients with Crohn's disease treated with anti-TNF antibodiesLior H Katz, Uri Kopylov, Ella Fudim, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 9, 2025
Performance of gastroenterologists and multimodal LLMs in endoscopic EREFS scoring of Eosinophilic EsophagitisAsaf Levartovsky, Lior Dar, Shmuel Fay, et al.
International Journal of Colorectal Disease|April 17, 2020
Infliximab levels and antibodies in IBD-related peripheral arthralgiaAsaf Levartovsky, Bella Ungar, Miri Yavzori, et al.
Gut|April 22, 2015
Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar RemsimaShomron Ben-Horin, Miri Yavzori, Itai Benhar, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 14, 2022
Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease - a retrospective studyMoran Livne-Margolin, Daniel Ling, Shani Attia-Konyo, et al.
United European Gastroenterology Journal|March 28, 2020
A novel PillCam Crohn's capsule score (Eliakim score) for quantification of mucosal inflammation in Crohn's diseaseRami Eliakim, Doron Yablecovitch, Adi Lahat, et al.
Pageof 9